$346 Million is the total value of ACUTA CAPITAL PARTNERS, LLC's 46 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 81.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ADVM | Buy | ADVERUM BIOTECHNOLOGIES INC | $36,467,000 | +119.0% | 1,746,500 | +2.5% | 10.54% | +30.5% |
| IMMU | New | IMMUNOMEDICS INC | $19,315,000 | – | 545,000 | +100.0% | 5.58% | – |
| BTAI | Buy | BIOXCEL THERAPEUTICS INC | $18,050,000 | +156.4% | 340,500 | +8.1% | 5.22% | +52.8% |
| IOVA | Buy | IOVANCE BIOTHERAPEUTICS INC | $16,196,000 | +35.4% | 590,000 | +47.7% | 4.68% | -19.3% |
| MRSN | Sell | MERSANA THERAPEUTICS INC | $14,801,000 | +206.8% | 632,500 | -23.6% | 4.28% | +82.9% |
| KURA | Buy | KURA ONCOLOGY INC | $14,222,000 | +621.9% | 872,500 | +340.7% | 4.11% | +330.3% |
| AVDL | Sell | AVADEL PHARMACEUTICALS PLCsponsored adr | $14,158,000 | -32.4% | 1,752,218 | -34.5% | 4.09% | -59.7% |
| CLDX | New | CELLDEX THERAPEUTICS INC NEW | $13,000,000 | – | 1,000,000 | +100.0% | 3.76% | – |
| ADAP | New | ADAPTIMMUNE THERAPEUTICS PLCsponds adr | $11,662,000 | – | 1,165,000 | +100.0% | 3.37% | – |
| RLMD | Buy | RELMADA THERAPEUTICS INC | $10,494,000 | +238.3% | 234,500 | +157.8% | 3.03% | +101.6% |
| LRMR | New | LARIMAR THERAPEUTICS INC | $10,272,000 | – | 823,169 | +100.0% | 2.97% | – |
| BCRX | Buy | BIOCRYST PHARMACEUTICALS | $9,054,000 | +1710.8% | 1,900,000 | +660.0% | 2.62% | +981.0% |
| CBIO | Buy | CATALYST BIOSCIENCES INC | $8,793,000 | +45.3% | 1,497,900 | +8.2% | 2.54% | -13.4% |
| KRTX | Buy | KARUNA THERAPEUTICS INC | $8,694,000 | +115.6% | 78,000 | +39.3% | 2.51% | +28.6% |
| IMVT | New | IMMUNOVANT INC | $8,523,000 | – | 350,000 | +100.0% | 2.46% | – |
| ASND | Sell | ASCENDIS PHARMA A Ssponsored adr | $8,208,000 | +15.3% | 55,500 | -12.2% | 2.37% | -31.3% |
| BLU | Sell | BELLUS HEALTH INC NEW | $7,872,000 | -26.3% | 765,000 | -28.5% | 2.27% | -56.1% |
| AXSM | Sell | AXSOME THERAPEUTICS INC | $7,405,000 | -59.2% | 90,000 | -70.8% | 2.14% | -75.7% |
| MRUS | New | MERUS N V | $7,401,000 | – | 460,000 | +100.0% | 2.14% | – |
| SELB | SELECTA BIOSCIENCES INC | $6,714,000 | +17.8% | 2,364,204 | 0.0% | 1.94% | -29.8% | |
| APLT | Buy | APPLIED THERAPEUTICS INC | $6,579,000 | +97.3% | 182,000 | +78.4% | 1.90% | +17.6% |
| KDMN | Sell | KADMON HLDGS INC | $6,554,000 | -33.7% | 1,280,000 | -45.8% | 1.89% | -60.5% |
| XENE | Sell | XENON PHARMACEUTICALS INC | $6,489,000 | -9.0% | 517,500 | -17.7% | 1.88% | -45.7% |
| APLS | Sell | APELLIS PHARMACEUTICALS INC | $6,205,000 | +10.5% | 190,000 | -9.3% | 1.79% | -34.1% |
| LSACU | LIFESCI ACQUISITION CORPunit 03/31/2025 | $6,160,000 | +10.0% | 560,000 | 0.0% | 1.78% | -34.4% | |
| ALT | New | ALTIMMUNE INC | $5,757,000 | – | 537,500 | +100.0% | 1.66% | – |
| VIR | New | VIR BIOTECHNOLOGY INC | $5,203,000 | – | 127,000 | +100.0% | 1.50% | – |
| VSTM | Sell | VERASTEM INC | $4,558,000 | -52.0% | 2,650,000 | -28.8% | 1.32% | -71.4% |
| DRNA | Sell | DICERNA PHARMACEUTICALS INC | $4,318,000 | -8.4% | 170,000 | -33.7% | 1.25% | -45.4% |
| ARVN | Sell | ARVINAS INC | $4,125,000 | -63.5% | 123,000 | -56.1% | 1.19% | -78.2% |
| ALDX | New | ALDEYRA THERAPEUTICS INC | $3,711,000 | – | 890,000 | +100.0% | 1.07% | – |
| AGEN | New | AGENUS INC | $3,665,000 | – | 932,500 | +100.0% | 1.06% | – |
| SNDX | New | SYNDAX PHARMACEUTICALS INC | $3,568,000 | – | 240,744 | +100.0% | 1.03% | – |
| ISEE | Buy | IVERIC BIO INC | $3,506,000 | +633.5% | 687,500 | +394.6% | 1.01% | +336.6% |
| RNA | New | AVIDITY BIOSCIENCES INC | $3,321,000 | – | 117,500 | +100.0% | 0.96% | – |
| EIGR | New | EIGER BIOPHARMACEUTICALS INC | $2,808,000 | – | 292,500 | +100.0% | 0.81% | – |
| QURE | Buy | UNIQURE NV | $2,704,000 | +7.5% | 60,000 | +13.2% | 0.78% | -35.9% |
| ARWR | Sell | ARROWHEAD PHARMACEUTICALS IN | $2,591,000 | -17.9% | 60,000 | -45.3% | 0.75% | -51.0% |
| RETA | Sell | REATA PHARMACEUTICALS INCcl a | $2,387,000 | -29.6% | 15,300 | -34.9% | 0.69% | -58.0% |
| FUSN | New | FUSION PHARMACEUTICALS INC | $2,358,000 | – | 135,000 | +100.0% | 0.68% | – |
| GBIO | New | GENERATION BIO CO | $2,100,000 | – | 100,000 | +100.0% | 0.61% | – |
| CRDF | New | CARDIFF ONCOLOGY INC | $2,042,000 | – | 407,500 | +100.0% | 0.59% | – |
| SURF | New | SURFACE ONCOLOGY INC | $1,476,000 | – | 225,000 | +100.0% | 0.43% | – |
| WVE | New | WAVE LIFE SCIENCES LTD | $1,119,000 | – | 107,500 | +100.0% | 0.32% | – |
| STSA | New | SATSUMA PHARMACEUTICALS INC | $1,007,000 | – | 35,000 | +100.0% | 0.29% | – |
| AKUS | New | AKOUOS INC | $500,000 | – | 22,200 | +100.0% | 0.14% | – |
| ABUS | Exit | ARBUTUS BIOPHARMA CORP | $0 | – | -269,907 | -100.0% | -0.13% | – |
| ZFGN | Exit | ZAFGEN INC | $0 | – | -1,386,000 | -100.0% | -0.52% | – |
| GBT | Exit | GLOBAL BLOOD THERAPEUTICS IN | $0 | – | -39,000 | -100.0% | -0.97% | – |
| MRNS | Exit | MARINUS PHARMACEUTICALS INC | $0 | – | -1,038,000 | -100.0% | -1.02% | – |
| CNST | Exit | CONSTELLATION PHARMCETICLS I | $0 | – | -139,464 | -100.0% | -2.12% | – |
| AUPH | Exit | AURINIA PHARMACEUTICALS INC | $0 | – | -770,000 | -100.0% | -5.42% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS INC | 24 | Q1 2023 | 21.2% |
| IRIDEX CORP | 20 | Q3 2019 | 8.1% |
| ARROWHEAD PHARMACEUTICALS INC | 20 | Q2 2023 | 7.9% |
| IMMUNOMEDICS INC | 19 | Q3 2020 | 20.6% |
| VERACYTE INC | 19 | Q3 2019 | 10.1% |
| ASCENDIS PHARMA A S | 18 | Q2 2020 | 7.2% |
| XENON PHARMACEUTICALS INC | 18 | Q3 2022 | 4.6% |
| CAS MED SYS PAR $0.004 | 18 | Q1 2019 | 6.4% |
| APELLIS PHARMACEUTICALS INC | 17 | Q3 2023 | 18.4% |
| KURA ONCOLOGY INC. COMMON STOCK | 17 | Q3 2023 | 8.1% |
View ACUTA CAPITAL PARTNERS, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| BCLS Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| Jiya Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Aadi Bioscience, Inc. | September 07, 2021 | 1,529,402 | 7.2% |
| Kadmon Holdings, Inc. | February 14, 2020 | 7,373,333 | 4.6% |
| IRIDEX CORPSold out | November 13, 2019 | 0 | 0.0% |
| ASSEMBLY BIOSCIENCES, INC. | February 14, 2019 | 718,500 | 2.8% |
| CAS MEDICAL SYSTEMS INC | February 14, 2019 | 5,263,508 | 18.2% |
View ACUTA CAPITAL PARTNERS, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View ACUTA CAPITAL PARTNERS, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.